Effectiveness in the prevention and control of tuberculosis – a comparative analysis of countries using data envelopment analysis by Gaspar, Ana Rita Salvé-Rainha
  
 
UNIVERSIDADE DO ALGARVE 
FACULDADE DE ECONOMIA 
 
 
 
EFFECTIVENESS IN THE PREVENTION AND CONTROL OF 
TUBERCULOSIS – A COMPARATIVE ANALYSIS OF 
COUNTRIES USING DATA ENVELOPMENT ANALYSIS  
 
ANA RITA SALVÉ-RAINHA GASPAR 
 
 
Dissertação para obtenção do grau de Mestre em Gestão de Unidades de Saúde 
 
Mestrado em Gestão de Unidades de Saúde 
 
Trabalho efetuado sob orientação de: 
Professora Doutora Carla Alexandra E. Filipe Amado 
Professor Doutor Sérgio Pereira dos Santos 
 
 
 
 
Faro 
 
2016
ii 
 
 
 
 
 
UNIVERSIDADE DO ALGARVE 
FACULDADE DE ECONOMIA 
 
 
 
 
EFFECTIVENESS IN THE PREVENTION AND CONTROL OF 
TUBERCULOSIS – A COMPARATIVE ANALYSIS OF 
COUNTRIES USING DATA ENVELOPMENT ANALYSIS  
 
ANA RITA SALVÉ-RAINHA GASPAR 
 
 
Dissertação para obtenção do grau de Mestre em Gestão de Unidades de Saúde 
 
Mestrado em Gestão de Unidades de Saúde 
 
Trabalho efetuado sob orientação de: 
Professora Doutora Carla Alexandra E. Filipe Amado 
Professor Doutor Sérgio Pereira dos Santos 
 
 
 
Faro 
 
2016 
iii 
 
DECLARAÇÃO DE AUTORIA E COPYRIGHT 
 
 
EFFECTIVENESS IN THE PREVENTION AND CONTROL OF TUBERCULOSIS – 
A COMPARATIVE ANALYSIS OF COUNTRIES USING DATA ENVELOPMENT 
ANALYSIS 
 
 
Declaro ser a autora deste trabalho, que é original e inédito. Autores e trabalhos 
estão devidamente citados no texto e constam da listagem de referências incluída. 
 
 
__________________________________________ 
Ana Rita Salvé-Rainha Gaspar  
 
 
 
 
Ana Rita Salvé-Rainha Gaspar Copyright © 
 
A Universidade do Algarve tem o direito, perpétuo e sem limites geográficos, de 
arquivar e publicitar este trabalho através de exemplares impressos reproduzidos em 
papel ou de forma digital, ou por qualquer outro meio conhecido ou que venha a ser 
inventado, de o divulgar através de repositórios científicos e de admitir a sua cópia e 
distribuição com objetivos educacionais ou de investigação, não comerciais, desde que 
seja dado crédito ao autor e editor. 
 iv 
 
TABLE OF CONTENTS 
   
ACKNOWLEDGEMENTS vii 
RESUMO viii 
ABSTRACT ix 
1. INTRODUCTION 1 
2. EFFECTIVENESS IN THE PREVENTION AND CONTROL OF 
TUBERCULOSIS 2 
2.1 PREVENTION AND CONTROL OF TUBERCULOSIS 2 
2.2 THE USE OF DATA ENVELOPMENT ANALYSIS TO ASSESS 
EFFECTIVENESESS 6 
3. DATA ANALYSIS 12 
3.1 DEA MODEL 12 
3.2 DATA AND EFFECTIVENESS RESULTS 17 
4. CONCLUSION 33 
5. REFERENCES 35 
 
 
 
 v 
 
LIST OF TABLES 
 
Table 1: Summary of the input and outputs included in the DEA model 15 
Table 2: Summary of the ratios between the TB cases included in each category 16 
Table 3: Number and type of TB cases treated by each of the 33 countries included in the study
 18 
Table 4: Data used in the DEA model regarding treatment success rates 20 
Table 5: DEA effectiveness scores and % contribution of each output to the score 23 
Table 6: Descriptive statistics of the scores and % contribution of each output to the score 24 
Table 7: Summary of Benchmarks (peers and lambdas) 26 
Table 8: Targets for non-effective countries 31 
 
 
 
 
 
 
 
 
  
 
 vi 
 
LIST OF ABBREVIATIONS 
 
AIDS – Acquired Immunodeficiency Syndrome 
CI – Composite Indicator 
CRS – Constant Return to Scale 
DEA – Data Envelopment Analysis 
DMU – Decision Making Unit 
DOTS – Directly Observed Treatment Short-coursed 
EMS – Efficiency Measurement System 
HBC – High Burden Country 
HIV – Human Immunodeficiency Virus 
MDR – Multi-drug resistance 
MDR-TB – Multi-drug resistant tuberculosis 
NTP – National Tuberculosis Control Program 
RR – Rifampicin Resistance 
RR-/MDR- - Rifampicin Resistant-/Multi-drug Resistant 
RR-/MDR-TB - Rifampicin Resistant-/Multi-drug Resistant Tuberculosis 
TB - Tuberculosis 
WHO – World Health Organization  
 vii 
 
ACKNOWLEDGEMENTS 
To my advisors, Professor Sérgio Santos and Professor Carla Amado, for all the 
availability, guidance and professionalism.  
To all those who, during this journey, were somehow harmed by my absence. The 
choices were not always easy and only your strength and your smile gave me the 
courage to continue. My success is due to you.  
  
  
 
 viii 
 
RESUMO 
A Tuberculose é a primeira causa de morte por doenças infeciosas em todo o 
mundo. O atual panorama de restrições que a maioria dos países atravessa, reforça a 
avaliação da eficiência e efetividade, como a única forma de orientação para que os 
investimentos feitos assentem sobre uma base sólida de boas práticas e melhoria 
contínua. 
O presente estudo tem como objetivo explorar o uso da técnica Data Envelopment 
Analysis (DEA) por forma a analisar o desempenho dos países no que se refere ao 
controlo da Tuberculose e identificar boas práticas como uma plataforma de melhoria. 
Para esse efeito, utilizamos dados de 33 países de baixo e médio rendimento referentes 
ao sucesso de tratamento. Os resultados mostram que o Bangladesh, Burundi, China e 
Paquistão são os únicos países efetivos na nossa amostra. Apesar da variação da 
efetividade entre países não ser substancial, os resultados mostram margem para 
melhorias e sugerem que uma melhor utilização dos recursos e práticas mais efetivas de 
prevenção e controlo podem ser estabelecidas. Além disso, os nossos resultados também 
apoiam o DEA como uma ferramenta versátil para o planeamento estratégico e tomada 
de decisões efetivas.  
Palavras-chave: Tuberculose, Prevenção e Controlo, Data Envelopment Analysis, 
Efetividade;
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ABSTRACT  
Tuberculosis (TB) is the first cause of death from infectious diseases worldwide. 
The current panorama of restrictions that most of the countries are experiencing, makes 
it necessary to assess efficiency and effectiveness as the only way to provide guidance 
so that the investments made can have a sound basis of good practice and continuous 
improvement. 
The present study proposes to explore Data Envelopment Analysis (DEA) to 
assess countries performance in TB prevention and control, and in doing so establish 
comparisons between countries and identify good practices as a platform for 
improvement. To achieve these objectives, we used data regarding TB treatment success 
from 33 low and middle income countries. Our results show Bangladesh, Burundi, 
China and Pakistan as the only effective countries in our sample. Despite the variation 
of effectiveness not being substantial, our results show margin for great improvement 
and suggest that a better use of resources and more effective practices regarding TB 
prevention and control can be established for the non-effective countries. Moreover, our 
results also support DEA as a versatile tool for effective strategic planning and decision 
making.  
Keywords: Tuberculosis, Prevention and Control, Data Envelopment Analysis, 
Effectiveness. 
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1. INTRODUCTION  
Tuberculosis (TB) is today, according to the World Health Organization (WHO), 
the number one cause of death from infectious diseases worldwide, along with the 
Human Immunodeficiency Virus (HIV). Despite all the efforts made, and knowing that 
TB is preventable and curable, numbers show that this disease has a global massive 
representation and creates an urgent need for effective strategies to control it and 
prevent the appearance of new cases. The WHO (2016) points to an estimated 10,4 
million new TB cases worldwide in 2015. This represents 800.000 more cases than 
those estimated in the report published in 2015. The high number of TB cases 
worldwide has major repercussions in countries’ budgets and creates financial gaps that 
can make treatment inaccessible for those who need.  
Treatment success (including completed treatment or cured patients) is 
remarkably important for TB control programs, as non-adherence can contribute to the 
ongoing spread of this disease and the emergence of multi-drug resistant TB (MDR-TB) 
in the community (Okanurak, Kitayaporn & Akarasewi, 2008). In this scenario, an early 
diagnosis of infected people and an adequate monitorization during the course of 
treatment are both milestones in stopping TB and the most effective strategy in 
preventing this disease from spreading.  
TB control programs face several difficulties and challenges throughout their 
implementation. The lack of a structured and solid funding, a poor government 
commitment and deep difficulties in implementation and surveillance require simple but 
effective measures, as we need to have in mind that the most affected TB countries are 
greatly affected by poverty. In these countries, wasting money with ideal but not real 
policies is not an option.  Indeed, it is imperative to assess if strategies and countries’ 
policies are truly effective and efficient. We need to be conscious that health systems 
everywhere could make better use of their resources, whether through better practices, 
more widespread use of generic products, better incentives to providers, or more fluid 
financial and administrative mechanisms (Chan in World Health Report, 2010). The 
current panorama of restrictions that most of the countries are experiencing, makes it 
necessary to take a more critical and reflexive look at the health policies and programs 
of the various countries. The assessment of efficiency and effectiveness plays an 
increasingly significant role, as the only way to provide guidance so that the 
investments made can have a sound basis of good practice and continuous improvement. 
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Data Envelopment Analysis (DEA), developed by Charnes, Cooper and Rhodes 
(1978), is a non-parametric linear programming technique intended to measure the 
relative efficiency of Decision Making Units (DMU). More than that, it allows the 
identification of best performers and the establishment of comparisons among countries 
through a benchmark group. The information obtained by the identification of best 
practices can guide decision makers in the definition of better policies to improve the 
performance of countries (Zanella, Camanho & Dias, 2013).  
Therefore, the aim of this study is to assess countries effectiveness in the 
prevention and control of TB by using the DEA technique. In doing so, we can establish 
comparisons between countries and identify the most effective practices so that others 
can learn through them. As far as we know, there are no published papers crossing DEA 
and countries performance regarding TB prevention and control. As a consequence, we 
believe that the present study will add valuable knowledge to this area. Furthermore, it 
is also our aim that managers, policy makers and decision takers use this knowledge as 
a platform for improvement.  
 
2. EFFECTIVENESS IN THE PREVENTION AND CONTROL OF 
TUBERCULOSIS 
2.1 PREVENTION AND CONTROL OF TUBERCULOSIS 
TB was declared a global public health problem in 1993 by the WHO and with 
this declaration, several strategies were developed to fight this disease. According to the 
WHO, TB was the 2nd cause of death from infectious disease worldwide in the year of 
2014. More recent data from the same organization, shows that the numbers have grown. 
In fact, TB became the 1st cause of death from infectious diseases worldwide in 2015, 
alongside HIV (WHO, 2015; WHO, 2016).  
Despite what seems to be a negative scenario with growing numbers playing a 
major role, it is important to notice that this increase can be due to increased reporting. 
Several countries, such as China, India, Egypt and Peru made substantial progress in 
their public health communicable diseases reporting systems. Particularly in China, 
public hospitals are responsible for 55% of all reported cases and a web-based system 
for the reporting of communicable diseases has been implemented.  
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Globally speaking, it is estimated that in 2015 alone, 10,4 million new cases of 
TB have emerged (WHO, 2016). This represents 6 million more new cases than in 2013 
and 800.000 more cases than first estimated by the WHO’s report from 2015. In 
financial terms, the expression of these numbers assumes enormous proportions in all 
countries budget. Indeed, the average cost per person in 2015, oscillated between 100-
1000 US dollars for drug-sensitive TB and 2000-20000 US dollars for MDR-TB (WHO, 
2016). The overall value of prevention, diagnosis and treatment in 2014 and 2015 was 
estimated to be over 6.6 billion US dollars (WHO, 2014; WHO, 2015).  
Since 1990 until 2015, TB mortality has fallen 47%. In all, effective diagnosis and 
treatment saved an estimated 43 million lives between 2000 and 2014 (WHO, 2015). 
The advances were indeed major, but effective management strategies are still needed. 
Despite all the efforts made, TB still holds an extremely significant role in the world of 
diseases, as it is estimated that 1.4 million persons died from TB in 2015 and for each 
three persons who develop TB, one is still either not diagnosed or not reported. In fact, 
TB remains a major public health problem. The lack of timely access to quality 
diagnostic and treatment services for vulnerable populations contributed to the spread of 
TB and drug resistance (Khan, Fletcher & Coker, 2016).  
In what refers to success rates, globally, the treatment success rate for people 
newly diagnosed with TB was 86% in 2013 (WHO, 2015; WHO, 2016). A level that 
has been maintained since 2005. Although the target of 85% treatment success imposed 
by the WHO was achieved, the numbers show discrepant scenarios among the six WHO 
regions. The highest treatment success rates in 2013, were observed in the Western 
Pacific Region, the South-East Asia Region and the Eastern Mediterranean Region with, 
92%, 88% and 91%, respectively. Whilst in the African Region the treatment success 
rate was 79%, the lowest numbers were observed in the Region of the Americas and the 
European Region, with 75% and 76%, respectively. This shows a severe increase in 
treatment success since 1995, however, the differences between regions provides 
evidence that best practices need to be identified. A learning process based on the 
experiences of the best practices regarding TB prevention and control is fundamental to 
improve the performance of the different regions and to achieve the WHO’s targets. 
Among all the countries that report information about TB to the WHO, there are 
22 that hold the highest incidence rate of TB. The WHO considers Angola, Bangladesh, 
Brazil, China, Democratic People’s Republic of Korea, Democratic Republic of Congo, 
Ethiopia, India, Indonesia, Kenya, Mozambique, Myanmar, Nigeria, Pakistan, 
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Philippines, Russian Federation, South Africa, Thailand, Tanzania, United Republic of 
Viet Nam, Cambodia, Central African Republic, Congo, Lesotho, Liberia, Namibia, 
Papua New Guinea, Sierra Leone, Zambia and Zimbabwe, to be the 22 high burden 
countries (HBC), as, together, they are responsible for 83% of all cases reported. 
According to data published in the Global Tuberculosis Report of 2015 (WHO, 2015), 
most of these countries have rates of new cases around 150 to 300 per 100.000 
inhabitants. Moreover, the mortality rate in these countries oscillated between 790.000 
and 1.100.000 deaths excluding deaths among HIV-positive patients. Between HIV-
positive patients the mortality rate fell between 280.000 and 360.000 deaths. The high 
numbers of cases, as well as the high mortality rates, which represent between 81% to 
85% of the global mortality rate, make clear the concrete and fundamental need for 
effective actions to fight this disease, not only for the obvious expenses associated with 
it but, and above all, to avoid the loss of health and quality of life that it causes. 
The prevention, diagnosis and treatment of TB is a challenge for all those who 
care about health and well-being and brings out the need for an efficient intervention 
guided by scientific knowledge and good management practices. It is remarkably 
important to understand if concerted efforts are truly effective and efficient. Indeed, 
when we talk about effectiveness (the extent to which the system achieves the 
objectives set) and efficiency (the extent to which the system uses the resources to 
maximize the delivery of services) we need to realize that there is potential to improve. 
For example, it has been argued that health systems could make better use of their 
resources, by implementing best practices, making a more widespread use of generic 
products, providing better incentives or applying more fluid financial and administrative 
mechanisms (Chan in the World Health Report, 2010). Effective action involves a 
systemic and agile look and requires proper management of resources. 
Due to this fact, the achievement of efficiency and effectiveness became a major 
priority for managers, directors and other stakeholders. There must be a clear 
understanding of the difficulty, but also the fundamental need, to systematically 
conjugate these two concepts. The search for efficiency and effectiveness should aim to 
guarantee not only the aspects of the best use of resources and the best possible results, 
but should also be seen as the only way to provide the best possible care to TB patients.  
TB control programs face several difficulties and challenges throughout their 
implementation. The lack of a structured and solid funding, a poor government 
commitment and deep difficulties in implementation and surveillance are examples of 
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these challenges (Jassal & Bishai, 2010). To address them, simple but effective actions 
are required. We need to have in mind that the most affected TB countries are greatly 
affected by poverty and therefore cannot waste money with ineffective and inefficient 
actions.  
Choosing the appropriate indicators is pointed out as a critical issue in monitoring 
and evaluating TB control programs (Cherchye, Moesen, Rogge & Van Puyenbroeck, 
2007; Cherchye, Moesen, Rogge, Van Puyenbroeck, Saisana, Saltelli, Liska and 
Tarantola, 2008). Indeed, some of the most important organizations in shaping 
healthcare policy have worked on this issue and developed methods to monitor and 
evaluate National TB Programs. In spite of this, to the best of our knowledge, there is 
no method available to compare, in aggregated terms, the performance of countries with 
respect to TB programs. However, as discussed by Cherchye et al. (2008), the WHO, 
the United Nations and other international organizations have developed composite 
indicators (CIs) to compare countries in other complex policy issues. These CIs 
aggregate the performance of several indicators into a single number. 
Indicators like coverage, case detection, and treatment success embody the three 
key global indicators recommended by the World Health Assembly for measuring 
national TB control program. The Compendium of Indicators for Monitoring and 
Evaluating National Tuberculosis Programs (WHO, 2004), clarifies, among concepts 
and other indicators, the use of these three indicators and explains how they should be 
interpreted.  Due to the importance of treatment success in preventing TB from 
spreading and drug resistance from developing, we felt the need to specifically refer to 
this concept. Indeed, the treatment success rate is defined as 
 
 “the percentage of a cohort of TB cases registered in a specified period 
that successfully completed treatment, whether with bacteriologic evidence 
of success (“cured”) or without (“treatment completed”)”  
(WHO, 2004: 37) 
  
Treatment success represents a clear benefit for the person itself, but more than 
that, it is an enormous step to stop TB from spreading. Therefore, treatment success is 
directly related to reduced TB mortality. As an indicator, TB treatment success 
measures the capability of a program to hold the patients through the, sometimes very 
long, course of treatment. 
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When, in 1991, the WHO set a target of 85% for this indicator, only those cases 
which had bacteriologic evidence of success after treatment (cure) were considered. 
Later, the WHO started including also the persons who have completed treatment even 
without evidence of being cured.  This target has been accomplished in the case of drug-
susceptible TB since 2007. However, when we refer to drug-resistant TB, the treatment 
success was only 48% in the year of 2012. This is a number far from the established 
targets and that shows the substantial improvements that need to be done.  
Assessing and monitoring TB in terms of treatment success, the objective of this 
dissertation, allows us to understand if countries strategies are producing effects and 
making progress is the fight against TB. In doing so, we can realize what countries are 
effective, identify their practices and learn from them, so that progress can be a constant 
process in countries’ agenda. Only an effective performance assessment can guarantee 
an adequate use of funds, improvements in quality of life and a safer world to live in.  
 
2.2 THE USE OF DATA ENVELOPMENT ANALYSIS TO ASSESS 
EFFECTIVENESESS 
To assess effectiveness there are many techniques that can be used. The most 
frequently used approaches for performance assessment are: ratio analysis, the 
parametric approach, and the non-parametric approach, known as Data Envelopment 
Analysis (DEA). Whilst the ratio analysis involves the comparison of several 
performance indicators in the form of ratios, the parametric approach involves the 
assessment of performance based on a comparison with a best practice frontier with a 
shape as hypothesized by the analyst. Concerning DEA, it involves the assessment of 
performance regarding a non-parametric performance frontier. As opposed to the 
parametric approach, DEA identifies the best practice frontier based on the observed 
data, without the need for assumptions about its shape. For this reason, as discussed by 
Hollingsworth (2003), DEA has become the dominant approach for performance 
assessment in healthcare as well as other sectors. 
Although initially intended to assess productive efficiency of “not-for-profit 
entities” (Charnes, Cooper & Rhodes, 1978: 1) participating in public programs, 
nowadays its use seem to have expanded to other realities. Cherchye et al. (2007) note 
that the scope of DEA has broadened substantially over the last two decades, including 
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macro-assessments of countries, productivity and performance assessments and several 
applications to composite indicators construction. 
Going back to the foundations of DEA, in what refers to productive efficiency, 
Farrell (1957) by continuing Koopmans (1951) and Debreu (1951) work, defined this 
concept as the product of technical and allocative efficiency. Being more specific, Kopp 
(1981) defines productive efficiency as the ability of production organizations to 
produce a well-specified output at minimum cost, where the output and factor inputs 
must be clearly specified by vectors of measurable features.  
Giving attention to Farrell’s definition, it becomes easy to understand that the 
concept of technical and allocative efficiency are indeed easily distinguished but at the 
same time connected to each other. The first one is associated with the production 
frontier, which considers that an organization is efficient when produces the maximum 
output from a specified set of inputs, while the second one measures an organization’s 
success in selecting an ideal set of inputs with a certain set of input prices (Cooper, 
Seiford & Zhu, 2011). Regarding allocative efficiency, Kopp (1981) clarifies that it 
involves the selection of the most adequate input mix that allocates factors to their 
highest valued uses and thus introduces the opportunity cost of factor inputs in the 
measurement of productive efficiency.  
Even though DEA has been mostly used to measure the relative efficiency of units, 
there are also a few authors using DEA to measure effectiveness. Golany (1988), 
Schinnar, Kamis-Gould, Delucia & Rothbard (1990), Asmild, Paradi, Reese & Tam 
(2007) and Amado & Dyson (2008) are examples of some authors that have used DEA 
with the aim of evaluating effectiveness. According to Asmild et al. (2007), in the 
absence of precise prices or other value measures, models incorporating weight 
constraints such as DEA models can be used to determine effectiveness. Indeed, when 
Golany (1988), affirms that effectiveness measures how close an entity performs 
relative to some given goals and argues that inefficiency is associated with waste, and, 
therefore, cannot be associated with effective operations, we can see the proximity 
between these two concepts.  
Generally speaking, effectiveness assesses the beneficial impact of strategies in 
real healthcare outcomes (the impact on the relevant stakeholders). It evaluates the 
extent to which the aims of a particular organization are achieved. When healthcare and 
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economics study fields cross over, effectiveness is in fact what makes more sense to 
measure and to have in consideration when strategies are planned. To talk about 
effective strategies is to talk about positive impact and about real changes in people’s 
quality of life.  
DEA was initially proposed by Charnes, Cooper & Rhodes (1978), and consists in 
a non-parametric linear programming model that allows to evaluate the performance of 
a set of DMUs and that considers that each DMU integrates a process of transforming a 
set of inputs (resources) into outputs (goods/ services) (Cooper, Seiford & Zhu, 2011). 
Overall, DEA measures efficiency by estimating an empirical production function 
which embodies the optimal amount of outputs that could be generated by the inputs 
(Golany, 1988; Lovell, Pastor & Turner, 1995). This said, a DMU’s 
efficiency/inefficiency is measured by the distance from the point which represents its 
input and output values to the production frontier. Furthermore, DEA gives the 
possibility of benchmarking in operations management and just requires general 
information of production and distribution (Cooper, Seiford & Zhu, 2011).  
More than simply compiling results of efficiency for each DMU, DEA also allows 
each unit to identify a benchmarking group. These groups are made by units that, 
despite sharing goals and priorities with other units, appear to have a better performance 
and so are considered to be more efficient (Santos, Amado & Santos, 2012; Dear & 
Dyson, 2008). In this respect, by comparing the inefficient units with the efficient ones, 
it is possible to find ways to reduce inefficiencies.  
In this regard, Cherchye et al. (2007) developed their work around CIs and weight 
restrictions. In what refers to CIs, they represent indices that compile several individual 
performance indicators. This aggregation is undertaken by applying a specific weight to 
each performance indicator and measures multi-dimensional concepts that cannot be 
captured by a single indicator. These authors explain the “benefit-of-the-doubt” 
approach to construct CIs, in which “the weighting problem is handled for each country 
separately, and the country-specific weights accorded to each sub-indicator are 
endogenously determined” (Cherchye et al., 2007: 119). In this perspective, the main 
idea is that a country’s good relative performance in one specific sub-indicator points to 
a higher policy significance. Since one does not have information about the true weight 
policy of a country, one can collect that information by identifying the country’s 
relative weaknesses and strengths (Cherchye et al., 2007; Cherchye et al., 2008). 
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Therefore, these authors named above, affirm that such a data-oriented weighting model 
is justified by the typical CI-context of uncertainty, and lack of consensus on an 
appropriate weighting scheme. 
The use of DEA to develop CIs has been very popular and numerous papers can 
be found illustrating its use. Cherchye, Moesen & Puyenbroeck (2004), Zanella et al. 
(2013) are just a few examples of studies that have used DEA with the “benefit-of-the-
doubt approach” to compare the performance of countries in several different contexts. 
In the case of Zanella et al. (2013), these authors used a CI based in 25 single indicators 
that underlie the estimation of the Environmental Performance Index, to assess 
countries’ environmental performance. To ensure that all countries were being 
evaluated homogeneously they imposed weight restrictions and identified which 
countries are examples of best practices and which need to improve their results. By 
comparing the obtained ranking of countries with the ranking of the Environmental 
Performance Index, they tested the robustness of the results and verified that a positive 
relation exists between the approaches.  
In the healthcare field, Santos et al. (2012), conducted a study to assess the 
efficiency in preventing mother-to-child HIV transmission. With a sample of 52 low 
and middle income countries, these authors also chose to impose weight restrictions and 
by that, to prevent the countries from attributing a null weight to the variables. Through 
their DEA model, they concluded that there are significant variations between countries 
in matter of services provided. Some of the countries could make a more efficient use of 
the resources and, in doing so, could increase their performance around 70%. Moreover, 
they identified the non-efficient countries, the countries with best practices and set 
targets for improvement. In fact, they showed the potential of the DEA features and 
their importance for strategic planning in healthcare.  
In any of the studies reported above, one of the main challenges faced by the 
authors was to identify the appropriate performance indicators to include in the analysis. 
By indicator we mean a section of information that provides evidence about a specific 
phenomenon. However, a single indicator is not enough to make assessments and take 
conclusions given that it is just a small piece of a multi-dimensional phenomenon. Thus, 
the composite indicators, as a combination of a set of sub-indicators, were developed to 
give a broader idea regarding the performance of an entity. They summarize complex 
and multi-dimensional issues in a mathematical combination of individual indicators 
 10 
 
that represent different dimensions of a concept, which cannot be captured by a single 
indicator (Saisana & Tarantola, 2002; Zanella et al., 2013).  
The CI’s construction formula adapted from Cherchye et al. (2007) is as follows: 
𝐶𝐼𝑗 = ∑ 𝑤𝑖𝑗
𝑚
𝑖=1
⋅ 𝑦𝑖𝑗 
In this, CIj (j=1,…, n) is the composite index for country j, n represents the 
number of DMU’s, m is the number of performance indicators, 𝑦𝑖𝑗   is the value of 
indicator i generated by country j (i = 1,... m) and wi the weight assigned to indicator i. 
The resulting composite index can vary between zero, that represents the worst possible 
performance, and 1 (the benchmark). 
The fact that DEA does not impose a rigid structure of input and output weights 
for each unit is also pointed as an advantage of this technique. Thus, the weights are 
identified by the optimization problem and assume values that allows each DMU to 
achieve the best possible efficiency result. This flexibility assumes important 
proportions when we intend to identify the inefficient DMU’s, as it validates that they 
are not capable of accomplishing efficient results even when we use a weight 
distribution that favors them. Therefore, because of this absolute freedom, in a 
conventional DEA model, there are some inputs and/or outputs that can assume a 
weight close to zero and, as a consequence, be almost ignored in the efficiency analysis, 
despite any previous information about the DMU’s purpose and alleged importance of 
that input/output. Lins, Silva & Lovell (2007), point this situation as one of the most 
severe limitations of the conventional DEA models.  
From this fact, rises the need to restrain the excess of freedom and impose limits 
to reach a balance between flexibility and data information. Indeed, several researchers, 
such as Wong & Beasley (1990), Roll, Cook & Golany (1991) and Dimitrov & Sutton 
(2010) tried to find this balance and created models with weight restrictions. Pedraja-
Chaparro, Salinas-Jimenez & Smith (1997) and Chercye et al. (2007), have also 
recognized the usefulness of these models and explained them in their work.  
However, imposing weight restrictions is not an easy task. Restricting weights can 
be a difficult task due to possible conflicting expert opinions on the proper restrictions 
and due to problems with infeasibility (Dimitrov & Sutton, 2010).  
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In terms of the formulation of weight restrictions, there are a number of 
approaches suggested in the literature, most of which operate on the basis of judgements 
of importance about the inputs and outputs, based on monetary values, or based on 
production trade-offs. In this paper, we are just going to explain weight restrictions 
based on the “trade-off approach”, proposed by Podinovski (2004), since this is the 
method we use in this dissertation. We have chosen to use this approach since, as 
discussed by Podinovski (2004), it has several advantages: it avoids infeasibility and it 
ensures that the performance targets are realistic. According to the same author, this 
method guarantees that the radial target of inefficient units is always producible, since 
the restrictions are formulated based on realistic technological trade-offs. This situation 
cannot be guaranteed when we define weight restrictions based on the other two 
approaches mentioned above (judgements of importance and monetary values). In these 
cases, the resulting efficiency assessment can no longer be interpreted as a realistic 
improvement factor (Podinovski, 2004; Podinovski, 2016).  
As the “trade-off approach” gives us the possibility of imposing restrictions and at 
the same time ensures that realistic targets are estimated, it seems the best choice for our 
model.  
In some contexts, we are interested in comparing countries with respect to their 
achievements, without being concerned about the level of resources that was used to 
produce the results. That means that we are interested in evaluating the relative 
effectiveness of the countries without a concern for the level of relative efficiency. In 
these cases, the DEA model needs to be modified to include a single unitary input and 
several outputs. According to Lovell et al., (1995: 509), “this assumption implies that 
one input, the helmsman, provides varying amounts of several services, and that every 
country-year observation has exactly one helmsman”. This single input is also called 
“dummy input” (Cherchye et al., 2007: 121). In this perspective, the results we obtain 
are focused only on the achievements without evaluating the inputs required to achieve 
them.  
Indeed, Amado, José & Santos (2016) developed their study around a benefit-of-
the-doubt DEA model related to the measurement of active ageing in the European 
Union, with output orientation and using a single unitary input. These authors present 
the mathematical formulation for the benefit-of-the-doubt model as follows: 
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hL= Min v  
Subject to: 
∑ 𝑢𝑟𝑦𝑟𝐿
𝑠
𝑟=1
= 1 
∑ 𝑢𝑟𝑦𝑟𝑗
𝑠
𝑟=1
− 𝑣 ≤ 0 
𝑣 ≥ 𝜀 > 0 
𝑢𝑟 ≥ 𝜀 > 0 
 
In this sense, s represents the number of outputs, ur is the output weight or the 
multiplier associated with output r, yr represent the outputs (r=1, …, r), hL is the 
relative score of the country, j represents each of the n countries (j, …, n) and v is the 
weight of the single input. For the present study, we add to this formulation 12 weight 
restrictions in the form of trade-offs, which will be presented in the next chapter.  
Based on this model, countries can take conclusions regarding their own results, 
compare their performances with the benchmarks and adjust their policies according to 
the best practices. Due to its characteristics, the model can be used to assess the 
effectiveness of countries. We would like to recall that assessing effectiveness assumes 
extreme importance in healthcare, not only for managers, directors and administrators, 
but also, and above all, for patients, as the only way to pursue excellence. 
 Despite the extensive use of DEA in the healthcare context, to the best of our 
knowledge, there are no published papers that compare countries in terms of the 
effectiveness of TB prevention and control. Due to this fact, the present paper 
undertakes the important task of exploring this issue with the aim to identify the most 
effective countries in this context, as well as understand the structures and processes 
that support their best practices.  
 
3. DATA ANALYSIS 
3.1 DEA MODEL  
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In order to choose the appropriate set of inputs and outputs for our DEA model, 
several documents were consulted. Unfortunately, as far as we are aware, there are no 
published studies we can refer to in what regards the use of DEA to assess countries 
effectiveness in TB prevention and control. Consequently, we constructed our model 
with the information provided by WHO’s annual reports, which include data about 
several indicators and allow us to choose the variables that are most suitable for the 
purpose of our study.  
Since the present dissertation focuses on an evaluation of effectiveness, in which 
the fundamental purpose is to maximize results/outcomes, the choice of inputs turned 
out to be very clear. Following the approach suggested by other authors (such as, for 
example, Cherchye et al., 2007), we used a single input equal to one, or in other words a 
“dummy” input. Its use only makes sense when we want a model that is only concerned 
with achievements. 
Based on our review of the WHO reports, we have selected the following four 
outputs to include in the DEA model: 
1. Treatment success rate for new and relapsed TB cases; 
2. Treatment success rate for previously treated TB cases, excluding relapses; 
3. Treatment success rate for HIV-positive TB cases; 
4. Treatment success rate for Rifampicin Resistant-/Multi-drug resistant- (RR-
/MDR-) TB cases. 
Treatment success, alongside with directly observed treatment, short-coursed 
(DOTS) coverage and case detection rate, is a key global indicator recommended by the 
World Health Assembly for measuring national TB program’s success.  
Adherence to TB treatment is especially important for TB control. Non-adherence 
can contribute to the ongoing spread of the disease and the emergence of drug-resistant 
TB in the community (Okanurak et al., 2008). Considering that TB treatment requires 
taking several drugs for at least 6–8 months and that numerous adverse effects can 
happen, patients do not always finish it. It should also be mentioned that, because after a 
few weeks of taking the drugs the patients start feeling better, the need for continuing 
treatment is sometimes not perceived by them and so they tend to abandon it. Therefore, 
treatment success rates are dependent on this adherence and evaluate the capability of 
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countries TB programs to retain the patients until the course of treatment is finished. Its 
importance is major in stopping TB globally.  
The calculation of this indicator is made by the following formula: 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑒𝑤 𝑠𝑚𝑒𝑎𝑟 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑝𝑢𝑙𝑚𝑜𝑛𝑎𝑟𝑦 𝑇𝐵 𝑐𝑎𝑠𝑒𝑠 𝑟𝑒𝑔𝑖𝑠𝑡𝑒𝑟𝑒𝑑 𝑖𝑛 𝑎
𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑒𝑑 𝑝𝑒𝑟𝑖𝑜𝑑 𝑡ℎ𝑎𝑡 𝑤𝑒𝑟𝑒 𝑐𝑢𝑟𝑒𝑑 +  𝑡ℎ𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑡ℎ𝑎𝑡 𝑐𝑜𝑚𝑝𝑙𝑒𝑡𝑒𝑑 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑒𝑟 𝑜𝑓 𝑠𝑚𝑒𝑎𝑟 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑝𝑢𝑙𝑚𝑜𝑛𝑎𝑟𝑦 𝑇𝐵 𝑐𝑎𝑠𝑒𝑠 𝑟𝑒𝑔𝑖𝑠𝑡𝑒𝑟𝑒𝑑
𝑡ℎ𝑒 𝑠𝑎𝑚𝑒 𝑝𝑒𝑟𝑖𝑜𝑑
 𝑋 100 
 
Treatment success rate is an outcome indicator, so it reflects the changes, or in 
other words the broader results, that are expected to occur with the use of the inputs. 
The numbers needed to calculate this indicator are reported quarterly to the WHO at a 
facility, district, regional and national level. For this study, we consider only the 
national level data as, according to the WHO (2004), it allows comparisons between 
countries.  
Specifically referring to our first output, it is important to clarify the term 
“relapsed cases” and to make a distinction between this and “previously treated cases” 
of TB. Some confusion may occur when we look at these two concepts. The WHO 
(2011) defines that the relapses occur in patients that had TB and after treatment stayed 
without it for a period. They consider these patients as having a new TB episode and not 
the same one. In contrast, previously treated cases (after failure or after default) are 
cases in which the prolongation of a TB episode requires a change in the treatment. 
Indeed, the new and relapsed cases are treated as one category of patients in what refers 
to reporting information to the WHO (our first output), and previously treated patients 
are handled in separate (our second output).  
About this second output, it is also important to emphasize that the cases that have 
been previously treated, have a higher probability of having a RR-/MDR-TB, and 
therefore should be tested for drug resistance. These patients require a treatment 
regimen that differs from patients that were not previously treated. 
In addition to classifying cases by their treatment history, the numbers published 
by the WHO are also differenced by HIV status and multi-drug resistance (MDR) status. 
Since the risk of having TB is estimated to be 26 to 31 times higher in people living 
with HIV than among those without HIV infection, this category of patients demands 
special attention and requires specific collaboration strategies between WHO’s HIV and 
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TB departments.  Consequently, our third output refers to “treatment success rate for 
HIV-positive TB cases”. 
Lastly, referring to the fourth output, it is important to clarify the RR-/MDR-TB 
definition. The WHO (2011) defines it as the infection caused by Mycobacterium 
tuberculosis resistant in vitro to the effects of rifampicin (RR) or isoniazid and 
rifampicin (MDR), with or without resistance to any other drugs. Therefore, this 
diagnosis is made based on drug sensibility tests, which may be crucial in defining the 
course of treatment for these patients. It is estimated that in 2015 there were 480.000 
cases of MDR-TB and 110.000 of RR-TB (WHO, 2016). Although the number of 
patients with this type of TB are significantly lower than the number of patients with 
drug-sensitive TB, treatment success is more difficult to achieve because treatment 
courses require adjustments to the drug resistances and last for at least 2 years. In 
WHO’s reports, the information about these patients are reported in separate and, 
because of that, this category is also handled in separate in our DEA model. 
It is important to emphasize that the right selection of outputs for the DEA model 
is fundamental for the robustness of the results we present below. These four outputs 
were selected because of their importance, recognized by the WHO, and having in 
attention the availability of the information. In fact, the choice of these outputs is 
justified by the need to treat the different categories of patients separately, but also by 
the fact that the reporting systems do not capture information regarding other TB high 
risk groups. The only at-risk groups for which information is available are HIV patients 
and RR-/MDR-TB patients, and so these were the separate groups that could be 
included.  
In summary, table 1 presents the input and outputs considered in our DEA model: 
Table 1: Summary of the input and outputs included in the DEA model 
Inputs Outputs 
Dummy input Treatment success rate for new and relapsed TB cases; 
Treatment success rate for previously treated TB cases, 
excluding relapses; 
Treatment success rate for HIV-positive TB cases; 
Treatment success rate for RR-/MDR- TB cases. 
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In terms of describing our DEA model, it is also relevant to clarify the restrictions 
imposed and why we choose to impose them. Considering that the countries under 
analysis (i.e. high burden TB countries) have the same generic goals regarding TB 
prevention and control, it was considered unacceptable and unrealistic to allow the DEA 
model to assign to their outputs very discrepant weights. Thus, we felt the need to limit 
the level of flexibility in the choice of weights, in order to avoid the possibility of some 
countries assigning a weight close to zero to some of the outputs.  
We consider that the analysis of the proportion of patients accounted by each 
output in the total of TB patients for a particular country, is a realistic piece of 
information that can be taken into account in the definition of the weight restrictions. To 
formulate these restrictions, we gave special attention to the maximum and minimum 
values of this ratio. Considering that they can translate the trade-offs expected to occur 
between outputs, based on this information, we can establish restrictions that reflect 
realistic information about the countries. Consider the following codification of 
variables: 
 
 “v1”: number of new and relapsed cases; 
 “v2”: number of previously treated cases, excluding relapses; 
 “v3”: number of HIV-positive TB cases; 
 “v4”: number of RR-/MDR-TB cases. 
 
Table 2 below shows the results we obtain when we divide the number of cases 
included in each of the 4 categories of outputs by the cases included in the others. 
Table 2: Summary of the ratios between the TB cases included in each category 
 v1/v2 v1/v3 v1/v4 v2/v3 v2/v4 v3/v4 
Maximum 294,33 8979,64 1774,38 192,65 73,06 445,37 
Minimum 4,19 1,26 1,95 0,03 0,06 0,04 
 
With these ratios, one can tell, for example, that in a given country for each 
successfully treated case of TB in previously treated patients, we have approximately 
294 new or relapsed cases also treated with success. This is the maximum ratio 
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observed. The minimum ratio observed is of 4,19. We have defined weight restrictions 
that limit the ratio of weights between variables to be consistent with the maximum and 
minimum ratios observed between the respective variables. 
 If we consider u1, u2, u3 and u4 as the weights assigned to outputs 1, 2, 3 and 4, 
respectively, the mathematical expressions stated above, reflect the weight restrictions 
we developed for our DEA model:   
 
(1) 4,19 ≤ 𝑢1/𝑢2 ≤ 294,33 
(2) 1,26 ≤ 𝑢1/𝑢3 ≤ 8979,64 
(3) 1,95 ≤ 𝑢1/𝑢4 ≤ 1774,38 
(4) 0,03 ≤ 𝑢2/𝑢3 ≤ 192,65 
(5) 0,06 ≤ 𝑢2/𝑢4 ≤ 73,06 
(6) 0,04 ≤ 𝑢3/𝑢4 ≤ 445,37 
 
In this respect, we have used a benefit-of-the-doubt DEA model with restrictions 
in the form of trade-offs, as proposed by Podinovski (2004) and explained above.  
With the objective of assessing each countries’ effectiveness, we used the 
Efficiency Measurement System (EMS) software, version 1.3.0, with a Constant 
Returns to Scale (CRS) assumption and an output orientation. This is not very common 
to find in literature, since most of the published papers that use the benefit-of-the-doubt 
approach, follow an input orientation. However, and having in mind that our study is in 
the healthcare context where the ultimate goal is to improve the outcomes, this choice 
seems to be more adequate for our DEA model. Zanella et al. (2013) is a clear example 
of a paper with this same perspective.  
 
3.2 DATA AND EFFECTIVENESS RESULTS  
The data used in this study relates to the performance of countries in what refers 
to Tuberculosis prevention and control. All the data is from the year of 2013, except for 
RR-/MDR-TB data. In this case, the values used are from the year of 2012 as data from 
2013 were not available. Among the 194 countries and territories that report information 
to the WHO, the selection of countries to integrate in this study sample, followed two 
inclusion criteria: 
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1. Availability of information for the year 2013 in the WHO Tuberculosis Report 
of 2015; 
2. Having treated at least 30 cases of each type (i.e. new and relapsed cases of TB; 
previously treated (excluding relapses) cases of TB; HIV-positive TB cases; RR-
/MDR-TB cases). 
Following these criteria, we excluded all countries with missing values on the 
reports and those with less than 30 cases of each type. The application of these criteria 
resulted in the selection of 33 countries, as shown in the table 3, below.  
Table 3: Number and type of TB cases treated by each of the 33 countries 
included in the study 
 
New and 
relapsed TB 
cases 
(2013) 
Previously 
treated TB 
cases, 
excluding 
relapses 
(2013) 
HIV-
positive TB 
cases 
(2013) 
RR-/MDR-
TB cases 
(2012) 
Cohort 
(n. º) 
Cohort 
(n. º) 
Cohort 
(n. º) 
Cohort 
(n. º) 
Argentina 8474 782 554 89 
Bangladesh 184077 6327 68 505 
Belarus 3034 222 138 2509 
Botswana 7254 124 4083 63 
Brazil 76543 6945 9460 825 
Burundi 7547 80 977 36 
China 841999 7847 4649 1906 
Colombia 11902 708 1489 99 
Dominican 
Republic 
2898 162 263 100 
Georgia 3098 779 31 623 
Guatemala 2978 36 243 39 
Haiti 16557 483 2857 62 
India 1243 171712 44027 14051 
Indonesia 325582 1521 2438 432 
Iran (Islamic 
Republic of) 
10884 305 284 62 
Kazakhstan 14456 464 340 7213 
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Kenya 81255 8445 31755 197 
Lesotho 9119 1619 7683 146 
Malaysia 23346 654 1510 74 
Mexico 20708 638 1230 133 
Namibia 8418 2192 4343 208 
Nigeria 91997 8404 7481 154 
Pakistan 289376 7217 37 858 
Peru 17265 2802 1016 1122 
Republic of 
Moldova 
3889 357 247 856 
Romania 15188 925 250 638 
Rwanda 5701 278 1448 58 
South Africa 321087 18292 191189 8084 
Tajikistan 5263 812 122 535 
Turkey 13170 239 32 291 
Uganda 44605 2572 16762 41 
Ukraine 29726 9149 7553 5556 
United Republic 
of Tanzania 
64053 1679 20320 45 
Mean 77657 8023 11057 1443 
Standard 
Deviation 
164644 29662 33775 3021 
Minimum 1243 36 31 36 
Maximum 841999 171712 191189 14051 
 
All the presented countries are low and middle income countries, among which, 
10 (Bangladesh, Brazil, China, India, Indonesia, Kenya, Lesotho, Namibia, Nigeria and 
Pakistan) are HBC. In terms of the six WHO regions, our sample has the following 
distribution: 
 Africa Region: Botswana, Burundi, Kenya, Lesotho, Namibia, Nigeria, 
Rwanda, South Africa, Uganda and Tanzania; 
 Americas Region: Argentina, Brazil, Colombia, Dominican Republic, 
Guatemala, Haiti, Mexico and Peru; 
 Eastern Mediterranean Region: Iran (Islamic Republic of) and Pakistan; 
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 Europe Region: Belarus, Georgia, Kazakhstan, Republic of Moldova, 
Romania, Tajikistan, Turkey and Ukraine; 
 South-East Asia Region: Bangladesh, India and Indonesia; 
 Western Pacific Region: China and Malaysia.  
In our opinion, having this diversified distribution in our sample assumes 
substantial importance, as it allows us to analyze the relative performance of some of 
the countries that most contribute to the high number of TB cases reported, and at the 
same time compare them with others that are not so affected by this disease in order to 
identify the best practices. The imposition of these criteria to select the countries, 
provides assurance regarding the robustness of the data and consequently of the results 
we obtain.  
Considering all the information provided above, we are now going to present table 
4 with the data regarding treatment success rates (%) for some of the countries studied:  
Table 4: Data used in the DEA model regarding treatment success rates 
Countries 
New and 
relapses, 
2013 
Previously treated, 
excluding relapses, 
2013 
HIV-
positive TB, 
2013  
RR-/MDR-
TB, 2012  
Output 1 Output 2 Output 3 Output 4 
Argentina 51 40 32 34 
Bangladesh 93 86 75 72 
Belarus 87 71 65 54 
Botswana 73 60 71 70 
Brazil 72 38 46 51 
Burundi 91 84 87 92 
China 95 90 82 42 
Colombia 71 42 45 48 
Dominican 
Republic 
83 51 65 72 
Georgia 80 69 68 48 
Guatemala* 84 67 62 69 
Haiti* 81 75 71 76 
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India 88 66 76 46 
Indonesia 88 64 49 54 
Iran (Islamic 
Republic of) 
87 82 66 48 
Kazakhstan 89 63 59 73 
Kenya* 86 78 79 83 
Lesotho* 70 62 66 64 
Malaysia 76 46 51 30 
Mexico 80 55 48 74 
Namibia* 86 71 81 68 
Nigeria* 86 83 80 62 
Pakistan 93 80 81 71 
Peru* 79 59 57 60 
Republic of 
Moldova 
80 39 52 59 
Romania 85 45 58 34 
Rwanda 85 75 76 98 
South Africa 78 69 76 49 
Tajikistan 88 82 66 66 
Turkey 86 38 53 66 
Uganda 75 67 73 80 
Ukraine 71 55 44 34 
United Republic of 
Tanzania 
91 79 72 73 
Mean 82,06% 64,58% 64,61% 61,21% 
Standard deviation 8,87% 15,56% 13,54% 16,81% 
Maximum 95% 90% 87% 98% 
Minimum 51% 38% 32% 30% 
 
By analyzing this table, it is possible to realize the great discrepancies existent 
between the countries. The fact that Argentina has a treatment success rate for new and 
relapsed cases of just 51% when China has 95% and the mean is 82,06%, indicates that 
several gaps still need to be filled and more effective strategies need to be established. 
 22 
 
With regards to treatment success among previously treated patients, excluding relapses, 
the differences are accentuated and the scenario is even less positive. Here, the mean is 
just 64,58%. A number far from WHO’s target of 85%. Moreover, although the 
maximum value for this rate is very similar to the maximum value observed for the first 
output (90% for China), when we refer to the minimum value the number is quite 
discrepant. In fact, Turkey has just 38% of treatment success among these patients. 
Specifically speaking about China, as one can tell by analyzing table 4, this 
country consistently shows high rates of treatment success, and leads the group in what 
refers to new and relapsed TB cases and previously treated TB cases. According to Lin, 
Wang, Zhang, Ruan, Chinc & Dyed (2015) several improvements in the Chinese 
healthcare system were made, as they recognized the impact of TB and the State 
Council of China implemented a 10-year program in 2001 that expanded services’ 
coverage. This can in fact justify these high success rates. Further information about 
China’s strategies will be provided bellow.  
When we turn our attention to the third output, having in mind that Argentina was 
the country with the lowest treatment success rate in output 1, it is not shocking to 
verify that the minimum value observed in this output also belongs to this country. 
Argentina has just 32% of success rate regarding HIV-positive patients with TB, 
followed by Ukraine with 44%. An interesting fact is that the country with the highest 
rate of success in the third output is Burundi (82%). However, this high success rate in 
terms of HIV positive TB cases turns to be not so surprising when we realize that 
Burundi also shows relatively high success rates in terms of outputs 1 and 2. 
In the fourth output is where we can notice a greater difference between countries, 
with a standard deviation of 16,81%. When focusing on the extreme values, we can 
compare, for example, Malaysia with a 30% treatment success rate, and Rwanda, which 
has the highest rate of all countries (98%). There is, therefore, a difference of 68% 
between these two countries. In general, analyzing the rate’s standard deviation for all 
outputs, the numbers are quite significant, especially when we report to previously 
treated patients, excluding relapses, and to RR-/MDR-TB patients. This high variation 
between countries suggests that there is potential for improvement in some countries 
and that high treatment success rates are achievable. Low rates in treatment success 
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suggest that the patients may not be receiving an adequate treatment and may receive a 
poor monitorization and control.  
Even though this analysis of the summary statistics allows us to have a first idea 
regarding the countries performance, and considering that trade-offs may occur between 
the treatment of the four types of patients, we need to undertake an analysis with DEA 
in order to identify the best practices. Table 5 shows the scores to all 33 countries from 
the DEA model presented above: 
Table 5: DEA effectiveness scores and % contribution of each output to the score 
 
DMU Score Output 1 Output 2 Output 3 Output 4 
1 Argentina 54,41% 95% 0% 0% 5% 
2 Bangladesh 100,00% 90% 4% 0% 6% 
3 Belarus 92,58% 96% 0% 0% 4% 
4 Botswana 80,71% 56% 1% 43% 0% 
5 Brazil 76,95% 95% 0% 0% 5% 
6 Burundi 100,00% 40% 9% 31% 20% 
7 China 100,00% 72% 16% 12% 0% 
8 Colombia 75,74% 95% 0% 0% 5% 
9 Dominican Republic 89,85% 92% 0% 0% 8% 
10 Georgia 85,07% 95% 0% 1% 4% 
11 Guatemala* 90,63% 92% 0% 0% 8% 
12 Haiti* 88,45% 75% 17% 0% 8% 
13 India 93,07% 95% 0% 1% 4% 
14 Indonesia 93,53% 96% 0% 0% 4% 
15 
Iran (Islamic 
Republic of) 
92,25% 78% 18% 0% 4% 
16 Kazakhstan 95,95% 92% 0% 0% 8% 
17 Kenya* 94,10% 91% 0% 0% 9% 
18 Lesotho* 76,42% 57% 1% 42% 0% 
19 Malaysia 79,90% 100% 0% 0% 0% 
20 Mexico 87,03% 91% 0% 0% 9% 
21 Namibia* 93,77% 57% 1% 42% 0% 
22 Nigeria* 93,61% 50% 12% 37% 1% 
 24 
 
23 Pakistan 100,00% 91% 0% 3% 9% 
24 Peru* 84,79% 95% 0% 0% 5% 
25 Republic of Moldova 85,65% 95% 0% 0% 5% 
26 Romania 89,34% 100% 0% 0% 0% 
27 Rwanda 97,61% 61% 2% 1% 36% 
28 South Africa 86,32% 56% 1% 43% 0% 
29 Tajikistan 94,56% 77% 17% 0% 6% 
30 Turkey 92,23% 95% 0% 0% 5% 
31 Uganda 83,90% 43% 1% 33% 23% 
32 Ukraine 74,82% 97% 0% 0% 3% 
33 
United Republic of 
Tanzania 
98,06% 92% 0% 0% 7% 
 
For a better understanding of these results, we now present the descriptive 
statistics: 
Table 6: Descriptive statistics of the scores and % contribution of each output to the 
score 
 Score Output 1 Output 2 Output 3 Output 4 
Mean 88,52% 82,00% 3,00% 9,00% 6,00% 
Maximum 100,00% 100,00% 18,00% 43,00% 36,00% 
Minimum 54,41% 40,00% 0,00% 0,00% 0,00% 
Standard deviation 9,62% 18,43% 5,88% 16,08% 7,37% 
 
Regarding table 5, we can observe that only 4 countries (Bangladesh, Burundi, 
China and Pakistan) are effective, 20 countries have scores higher than 85% and just 1 
has a score lower than 70%. The average of the effectiveness score is 88,52%, which 
demonstrates margin for improvement but at the same time validates the efforts that 
have been undertaken in some countries to pursue effectiveness in TB prevention and 
control. The standard deviation is 9,62%, which indicates that there are some 
differences between the performance of the countries. However, this value does not 
translate the gap that exists between some of the countries, which is larger and demands 
effective changes in countries programs. That difference is more perceivable when one 
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focuses the attention on the minimum and maximum value of the score. For example, 
Argentina has a score of 54,41%, which is 34,11% lower than the average score of all 
countries. This difference makes clear that great changes need to be implemented, the 
reasons behind the gap need to be identified and Argentina must learn from effective 
countries.  
In order to fully understand countries performance, we need to analyze the 
contribution of each output to the overall effectiveness score. The last four columns of 
Table 6 present the optimal share of contribution of each output to the score. It is 
important to emphasize one aspect. The shares of contribution presented in table 5 are 
rounded values. Whilst in some cases, we can observe a null share of weight attributed 
to some outputs, this does not correspond to zero weight. In fact, this corresponds to a 
weight which is very close to zero. Similarly, when a 100% contribution is attributed to 
some outputs, this corresponds to a contribution that is close to 100%. 
Therefore, in terms of optimal weight distribution, we can see different scenarios 
among the 33 countries and by analyzing them we can extract valuable information 
about the strategies implemented by countries. The first output, which has a mean of 
contribution of 82%, is, clearly, the one with more representation in the effectiveness 
score. We can observe that all countries benefited from the attribution of the largest 
share of weight to the first output, which is not surprising, given that, except for 
Burundi, Uganda and Rwanda, the best treatment success rate for all countries is for 
new and relapsed cases. At the extreme, we can observe two countries (Malaysia and 
Romania) that have actually benefited from the attribution of almost the totality of the 
weight to the first output. Generally, while Malaysia and Romania benefited from this 
weight distribution, others benefited from the distribution of the weight into two or 
three outputs, and only 4 countries benefited from the distribution through all four. 
Concerning the second output, this is the one with the lowest mean of contribution 
of all 4 outputs, with just 3%. In addition, 20 countries assigned it a close to zero weight 
and the remaining countries have put between 1% and 18% of the weight on this output. 
With this, output 2 appears to be one of the less contributive to the effectiveness score 
alongside with output 4. In the case of the fourth output, 8 countries put a weight close 
to zero on it and the other countries benefited from the attribution of a weight between 
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1% and 36%. Among this last group, 23 countries chose to put less than 10% of their 
weight into RR-/MDR-TB cases. 
With regards to the third output, 21 countries assigned a close to zero weight to it 
and 4 countries assigned less than 10% of the weight to this output. This situation is 
expected since we know that the choice of the weights follows the scheme that most 
benefits the countries, and, in the case of HIV-positive TB cases, the treatment success 
rates are lower than in other cases. However, 7 countries have assigned more than 30% 
of their weight to this output, which are the countries with highest treatment success 
rates for this category of patients (see for example Burundi) and countries that have 
divided the weight more equally through the four outputs in our DEA model (see for 
example Uganda).  
When we analyse the optimal share of contribution of the outputs chosen for each 
country, it is more prudent to take conclusions about the non-effective countries rather 
than the effective ones. This occurs because this weight distribution is the one that 
maximizes their effectiveness score and if they are not effective in this scenario, they 
will not be in any different one. However, one cannot have this certainty about effective 
countries. For the effective countries, there is a possibility of existing a different weight 
distribution that produces the same effectiveness results and, if this is the case, the 
interpretation of the relative importance of each output can assume completely 
difference values. Cooper, Ruiz & Sirvent (2007) corroborate this by affirming that, for 
the units that score 100%, we may have different optimal weights associated with the 
performance score of a given unit and this may provide very different insights into the 
role played by the variables used in the performance assessment.  
In what refers to the effective countries, table 8 allows us to see that China and 
Bangladesh assume the strongest positions as benchmarks, since they serve as an 
example for 20 different non-effective countries. After them, Burundi is a reference for 
14 countries and Pakistan for only 2. The reason for this situation relates to the weight 
scheme that these countries have used. Countries with unusual weight distribution tend 
to be the reference for a low number of non-effective countries. The following table 
presents the peers (effective countries that act like benchmarks) and the lambdas 
(weight of each peer) for every country: 
Table 7: Summary of Benchmarks (peers and lambdas) 
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DMU Benchmarks 
Argentina  Bangladesh (0,63)  China (0,37)  
Bangladesh 20 
Belarus  Bangladesh (0,51)  China (0,49)  
Botswana  Burundi (0,89)  China (0,11)  
Brazil  Bangladesh (0,72)  China (0,28)  
Burundi 14 
China 20 
Colombia  Bangladesh (0,63)  China (0,37)  
Dominican Republic  Bangladesh (0,69)  Burundi (0,31)  
Georgia  Bangladesh (0,26)  China (0,52)  Pakistan (0,21)  
Guatemala*  Bangladesh (0,84)  Burundi (0,16)  
Haiti*  Bangladesh (0,31)  Burundi (0,69)  
India  Bangladesh (0,02)  China (0,78)  Pakistan (0,20)  
Indonesia  Bangladesh (0,45)  China (0,55)  
Iran (Islamic Republic of)  Bangladesh (0,32)  China (0,68)  
Kazakhstan  Bangladesh (0,88)  Burundi (0,12)  
Kenya*  Bangladesh (0,20)  Burundi (0,80)  
Lesotho*  Burundi (0,83)  China (0,17)  
Malaysia  China (1,00)  
Mexico  Bangladesh (0,46)  Burundi (0,54)  
Namibia*  Burundi (0,61)  China (0,39)  
Nigeria*  Burundi (0,48)  China (0,52)  
Pakistan 2 
Peru*  Bangladesh (0,92)  China (0,08)  
Republic of Moldova  Bangladesh (0,80)  China (0,20)  
Romania  China (1,00)  
Rwanda  Burundi (1,00)  
South Africa  Burundi (0,30)  China (0,70)  
Tajikistan  Bangladesh (0,92)  China (0,08)  
Turkey  Bangladesh (0,88)  China (0,12)  
Uganda  Burundi (1,00)  
Ukraine  Bangladesh (0,06)  China (0,94)  
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United Republic of 
Tanzania 
 Bangladesh (0,90)  Burundi (0,10)  
 
As we mentioned before, China and Bangladesh are the strongest benchmarks 
(these countries work as benchmark to a large number of non-effective countries) and 
for that reason it is important to identify and understand their strategies, practices and 
how they overcome their problems, so that other countries can learn from them. In the 
case of China, there were several improvements and new strategies implemented that 
can justify this performance. Primarily, these results can be attributed to the expansion 
to the entire country of the DOTS program, implemented in 2001 by the Chinese Center 
for Disease Control and Prevention (Lin et al., 2015). By implementing this program, 
they were able to increase coverage and treatment success, since during the entire 
course of treatment, the medication is provided and directly observed by a healthcare 
worker. With this, patients’ adherence to the treatment was significantly improved. 
Moreover, according to WHO (2013), in China, the cost of TB treatment, provided as a 
public service, is covered by domestic healthcare budgets, often supplemented by 
international grants or loans. Olson, English & Claiborne (2014) refer that MDR-TB is 
covered by medical insurance for all patients and close to 70% of the entire cost is 
returned to the patient. This helps to reduce the financial barriers and financial burden 
of the disease which could lead to giving up treatment.  
In addition to all this, several other improvements in the Chinese programs are 
worth to be pointed out. Indeed, the Chinese government has been investing in 
diagnostic technologies and scientific research to contribute to the development of new 
drugs and drug regimens. Cell phones have been used in a pilot study to alert or remind 
patients to take medicine and to convey information about the side effects of treatment 
to physicians (Olson et al., 2014).  
In the case of Bangladesh there are also numerous policies and events that may 
justify the good performance of this country. This country is, like China, under the 
DOTS strategy, which started covering 99% of all population in 2003. In 2010, a five-
year cooperative agreement led by the United States Agency for International 
Development, supported a project called TB CARE II Bangladesh financed by the 
Global Fund and the Government of Bangladesh. With this project, Bangladesh could 
fill its gaps with major emphasis on universal and early access to TB services, 
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Programmatic Management of Drug Resistant TB and health systems (Government of 
the People’s Republic of Bangladesh, 2013). Moreover, laboratories quality assurance 
and support systems at all levels, were also a concern. In fact, the National Tuberculosis 
Control Program (NTP) has been improving since it was first implemented and 
preserves high treatment success rates, having achieved WHO’s target of 85% treatment 
success from 2003 until now.    
Since Bangladesh is a low-income country, an important problem to address is the 
financial burden of TB. Intending to overcome this issue, according to the Annual 
Report of Tuberculosis Control in Bangladesh from 2013, the NTP guaranteed free 
diagnostic and treatment services in all Upazila Health Complex, 44 Centers for Disease 
Control, 12 Chest Disease Hospitals, workplaces, prisons, etc. All these strategies made 
a significant difference on Bangladesh’s approach to TB patients, and that difference is 
shown by its performance results presented above.  
In the case of Burundi, the success achieved in the treatment of HIV-TB cases 
(where the country achieves the highest treatment success rate) can also be explained by 
some important policies and strategies that were implemented. Even though Burundi 
has reduced financing capacity, the money donated by the Global Fund to Fight 
Acquired Immunodeficiency Syndrome (AIDS), Tuberculosis and Malaria and other 
partners, gave them the opportunity to fill the gaps in the existing programs and 
improve results. Indeed, the United States Department of State (2015), emphasizes that 
the following strategies have contributed for the improvement of TB results in Burundi: 
systematic HIV testing among TB patients through the integration of HIV testing in all 
centers of TB care: surveillance of HIV sero-prevalence among TB patients; systematic 
integration of HIV prevention messages in structures for management of tuberculosis; 
early initiation of antiretroviral therapy for patients on TB treatment; and capacity 
building in centers for diagnosis and treatment so that they are able to provide quality 
services with a regular supply of drugs, equipment and consumables necessary for the 
diagnosis and treatment of co-infected patients. 
The last of the effective countries, is Pakistan. Despite this country being a 
reference (benchmark) for only 2 other countries, its performance score requires 
attention. In fact, the effectiveness of this country has its foundations in some strategies 
that were implemented. According to the Global Tuberculosis Report (WHO, 2016), 
Pakistan has established partnerships between the public and private sectors, which led 
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to the implementation of an active screening for TB in private clinics, private hospitals 
and laboratories, and guaranteed access to new faster diagnostic tests in private clinics 
at a low or zero cost. The implementation of this partnerships translated in the increase 
of the numbers of case notifications and improved patient’s monitorization. More 
specifically, the number of case notifications in the city of Karachi doubled in one year 
(WHO, 2016).  
The treatment success rates for Pakistan are quite balanced. It’s highest treatment 
success rate, like most countries, regards to new and relapsed cases of TB. The HIV-
positive TB cases has 81% treatment success and previously treated TB cases, 
excluding relapses has 80%. The lowest treatment success rate refers to RR-/MDR-TB 
cases. This is due to a severe problem with resistant TB, as high levels of ofloxacin 
resistance were found in this country (WHO, 2016). According to Metzger, Baloch, 
Kazi1 & Bile (2010), additional strategies funded by global and national sources, have 
contributed to the significant improvement in case detection and to the treatment 
success rates outlined above. These authors identify improvements in surveillance and 
laboratory network and improvements in patients’ follow-up and treatment modalities 
as the most significant changes in Pakistan’s TB control program.  They explain that  
“a 5-year plan was devised leading to universal DOTS coverage in the 
public sector towards the end of 2005. The funding was lined up efficiently 
by the federal Ministry of Health and provincial Departments of Health, 
with responsibilities delineated and TB control activities integrated into 
the primary health care system.” 
(Metzger et al., 2010: 49) 
Despite Rwanda not being considered one of the effective countries, the treatment 
success rate of this country regarding RR-/MDR-TB deserves some attention. The 
treatment of this category of patients suffered several alterations and because of that 
Rwanda shows the highest treatment success. Rwanda recognized that there were in the 
country high numbers of cases of MDR-TB and implemented several improvements to 
address this problem, which translated in better results. Specifically speaking, Rwanda 
went from a “twice a week” treatment in 1990, to a daily treatment in 2006. The 
previous intermittent intake of medicines resulted in the appearance of MDR-TB cases 
and created the need of effective strategies. In 2000, the Rwandan government created a 
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plan with the primary objective of rapidly transforming Rwanda into a middle-income 
country, in which health was identified as a key pillar in the government’s vision for 
economic development and poverty reduction (United Nations Office for Project 
Services, 2014). With this program, it was possible to start undertaking home visits for 
patients lost to follow-up and to improve treatment surveillance and monitorization.  
Regarding the information provided by table 8, it is important to clarify how one 
should interpret the values presented for each of the non-effective countries. Indeed, the 
name of the country that is presented before the parenthesis is the peer, or in other 
words, the effective country that the non-effective country should have as an example to 
improve its own results. The number between parenthesis is the lambda (λ), or the 
coefficients that should be applied to the output values of each peer in order to estimate 
the target value for the non-effective country. In fact, with this information, DEA allows 
us to analyze which countries serve as benchmark for the non-effective ones, the weight 
of that influence and which effective countries are the strongest and serve as 
benchmarks for a larger group. Moreover, one can easily calculate the targets for each 
non-effective country.   
The calculation of targets for non-effective countries is an interesting tool. 
Argentina has an improvement score of 183,79%, obtained by calculating the 
mathematical inverse of its effectiveness score presented in table 6. This score means 
that Argentina should be able to improve its performance by 83,79%.  However, one 
does not know which values should the treatment success rates for each type of TB 
assume. This is only possible by calculating the targets for each non-effective country, 
as shown by the following formula. Consider that: “Tx1” is the target for the treatment 
success rate for new and relapsed cases (output1) for country x; “B1” is the treatment 
success rate of peer 1; “B2” is the treatment success rate of peer 2; λ1 is the weight of 
peer 1; λ2 is the weight of peer 2. 
𝑇𝑥1 = (𝐵1 λ1) + (𝐵2λ2) 
 
Following this method, table 8 shows the targets for each non-effective country: 
Table 8: Targets for non-effective countries 
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DMU Output 1 Output 2 Output 3 Output 4 
Argentina 94% 87% 78% 61% 
Belarus 94% 88% 78% 57% 
Botswana 91% 85% 86% 87% 
Brazil 94% 87% 77% 64% 
Colombia 94% 87% 78% 61% 
Dominican Republic 92% 85% 79% 78% 
Georgia 93% 86% 79% 55% 
Guatemala 93% 86% 77% 75% 
Haiti 92% 85% 83% 86% 
India 95% 88% 82% 48% 
Indonesia 94% 88% 79% 56% 
Iran (Islamic 
Republic of) 
94% 89% 80% 52% 
Kazakhstan 93% 86% 76% 74% 
Kenya 91% 84% 85% 88% 
Lesotho 92% 85% 88% 84% 
Malaysia 95% 90% 82% 42% 
Mexico 92% 85% 81% 83% 
Namibia 93% 86% 85% 73% 
Nigeria 93% 87% 84% 66% 
Peru 93% 86% 76% 70% 
Republic of Moldova 93% 87% 76% 66% 
Romania 95% 90% 82% 42% 
Rwanda 91% 84% 87% 92% 
South Africa 94% 88% 84% 57% 
Tajikistan 93% 86% 76% 70% 
Turkey 93% 86% 76% 68% 
Uganda 91% 84% 87% 92% 
Ukraine 95% 90% 82% 44% 
United Republic of 
Tanzania 
93% 86% 76% 74% 
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With this information, and the information regarding their specific peers, each 
country can plan strategies in order to achieve the specific values proposed as target for 
each of the outputs. The success rates observed for some countries are already close to 
the proposed targets, and therefore only small improvements are necessary. Others, like 
Argentina or Brazil, are far from their targets and because of that, deeper changes are 
needed to fill the gaps. Having effective countries as reference for reconsidering their 
own practices is a useful strategy that can lead them to effective results. For example, 
Argentina and Brazil can develop strategies based on the best practices observed in 
Bangladesh and China, which we discussed previously. 
 
4. CONCLUSION 
Regarding the seriousness of the world situation and the worrying spread of TB, 
public policies that can effectively improve the quality of life of the population 
represent an urgent need.  For the structures responsible for national TB programs, it is 
necessary that effective actions are implemented to ensure detection, treatment and 
prevention of TB. Despite all the efforts made and the several strategies undertaken in 
TB prevention and control, this disease stills poses a massive health problem with huge 
social and economic impacts. The WHO (2016) points to 6.1 million new TB cases in 
2015 and makes clear that gaps in financing, prevention, treatment monitorization and 
control must be filled.  
To the best of our knowledge, there are no contributions exploring countries 
effectiveness in TB prevention and control through DEA analysis. Consequently, it is 
our aim that the present study makes a significant contribution to the knowledge in this 
area. With this intention, we have proposed a DEA model to analyze the performance of 
33 low and middle income countries regarding the treatment success rates in TB 
prevention and control. In this model, we have included one single unitary input and 4 
outputs.  
Despite the practical and relatively simple use of DEA, this study faced several 
obstacles and challenges through its development. Data unavailability for more recent 
years and the existence of missing values for a high number of countries in WHO’s 
reports, represents, probably, the most relevant challenge. In fact, information about 
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treatment success rates is missing for numerous countries for the year of 2013 and those 
who have information, sometimes it does not comprehend all types of TB or patients’ 
categories. Moreover, information available for most of the countries, covers just a 
single year or, when it covers more than one year, it is not for consecutive years. 
Because of this, we were unable to perform a dynamic analysis of the performance of 
countries but we believe that the present DEA model allowed some relevant findings. 
We also advise some caution in the interpretation of the results for Guatemala, Haiti, 
Kenya, Lesotho, Namibia, Nigeria and Peru (countries marked with the sign * in Tables 
6 and 8) as for these countries output 1 does not include the relapsed cases. These cases 
are accounted in output 2. Considering that none of these countries was considered 
effective, that means that their TB treatment success rates did not impact the 
effectiveness scores of the other countries. However, considering that the prognosis of 
treatment for new and relapsed cases is better that for previously treated TB cases, 
excluding relapses, it is likely that the effectiveness scores for these countries are 
overestimated.  
Other important challenge we faced relates to the selection of the weight 
restrictions imposed in the DEA model. In fact, one needs to consider the possibility 
that the selected weight restrictions may benefit the effective countries and, by imposing 
a weight scheme far from the real priorities of the countries, we might make them look 
effective when in reality they are not. Although we have pointed above several studies 
that have used weight restrictions, further investigation about this issue needs to be done 
in order to guarantee meaningful conclusions.  
Despite the exploratory nature of this study, there are some important conclusions 
that need to be highlighted. Among the 33 countries, China, Bangladesh, Burundi and 
Pakistan were considered effective in TB prevention and control. Although the standard 
deviation of the performance scores does not constitute a very surprising number, the 
analysis case by case showed significant variation in some countries. This indicates that 
countries could make better use of their resources and consequently achieve better 
results. Furthermore, our study allowed the identification of the benchmarks and some 
of their best practices, and helped establish specific targets so that the non-effective 
countries can plan strategies in order to achieve those targets. Regarding the 
identification of the specific causes behind poor performance and the reasons why 
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specific strategies are not being effective in TB prevention and control, deeper 
investigation deserves to be done.  
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